<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2018-5-17-24</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-892</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФАРКТ МИОКАРДА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MYOCARDIAL INFARCTION</subject></subj-group></article-categories><title-group><article-title>Предикторная значимость биомаркеров воспаления в отношении постинфарктного ремоделирования миокарда</article-title><trans-title-group xml:lang="en"><trans-title>Predictor value of the inflammation biomarkers regarding the post-infarction remodeling of myocardium</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4063-2005</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Резидент кардиолог.</p><p>Кишинев</p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">mihaela778@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7500-0625</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попович</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Popovich</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попович Иван Михайлович — доктор медицинских наук, профессор, академик АН Республики Молдова, заведующий отделом интервенционной кардиологии.</p><p>Кишинев, +7 (373-022) 72-75-11</p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">popovicim@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3583-4051</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чебан</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheban</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чебан Лучия Михайловна — доктор медицинских наук, старший научный сотрудник отдела интервенционной кардиологии НИИК , врач кардиолог МБ Novamed.</p><p>Кишинев</p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">vittorio@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0371-0791</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попович</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Popovich</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попович Иван Михайлович — доктор медицинских наук, профессор, директор.</p><p>Кишинев</p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">ion.popovici@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9258-2092</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующий отделом сердечной недостаточности.</p><p>Кишинев</p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">popovicim@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6141-1108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кобец</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kobets</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кобец Валерий Андреевич — доктор медицинских наук, профессор кафедры патофизиологии, 08324</p><p>Кишинев</p><p> </p></bio><bio xml:lang="en"><p>Kishinev</p></bio><email xlink:type="simple">valcobe@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ кардиологии</institution></aff><aff xml:lang="en"><institution>Cardiology Research Center</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>НИИ кардиологии; Многопрофильная больница Novamed</institution></aff><aff xml:lang="en"><institution>Cardiology Research Center; Multi-specialty hospital Novamed</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Многопрофильная больница Novamed</institution></aff><aff xml:lang="en"><institution>Multi-specialty hospital Novamed</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Институт кардиологии</institution></aff><aff xml:lang="en"><institution>Cardiology Research Center</institution></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Государственный университет медицины и фармации “Н. Тестемицану”</institution></aff><aff xml:lang="en"><institution>Nicolae Testemitanu State University of Medicine and Pharmacy</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2018</year></pub-date><volume>17</volume><issue>5</issue><fpage>17</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Иванов М.В., Попович М.И., Чебан Л.М., Попович И.М., Иванов В.М., Кобец В.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Иванов М.В., Попович М.И., Чебан Л.М., Попович И.М., Иванов В.М., Кобец В.А.</copyright-holder><copyright-holder xml:lang="en">Ivanov M.V., Popovich M.I., Cheban L.M., Popovich I.M., Ivanov V.M., Kobets V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/892">https://cardiovascular.elpub.ru/jour/article/view/892</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучение характера изменения циркулирующего уровня про-и антивоспалительных биомаркеров, а также металлопротеиназы-8 (ММП-8) в первые 7 сут. после реваскуляризации у пациентов с острым инфарктом миокарда с подъемом сегмента ST (ОИМ↑ST) с целью выявления их прогностической значимости в отношении паттерна постинфарктного ремоделирования миокарда.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. У 113 больных ОИМ↑ST, развившимся через 5 мес. после ангиопластики адаптивное ремоделирование миокарда (АРМ) (n=56) или патологическое ремоделирование миокарда (ПРМ) (n=57), определили методом иммуноферментного анализа ежедневную сывороточную концентрацию провоспалительных: высокочувствительный С-реактивный белок (вчСРБ), интерлейкины (ИЛ) 1, 6, фактор некроза опухоли альфа и моноритарный хемоатрактивный протеин-1, антивоспалительных биомаркеров: ИЛ-4, ИЛ-10, ИЛ-33, антагонист рецептора ИЛ-1 и херегу-лин-1бета, а также ММП-8 до и в первые 7 сут. после реваскуляризации миокарда. Обе группы пациентов по основным клиникодемографическим показателям были сопоставимы. Полученные биохимические данные сравнивали между группами, а также с контрольными биомаркерами, определяемыми у 20 здоровых лиц (контрольная группа).</p></sec><sec><title>Результаты</title><p>Результаты. Динамика изученных провоспалительных биомаркеров после реваскуляризации оказалась схожей у больных с АРМ и ПРМ. Она характеризовалась достоверным увеличением их содержания к 3 сут., после чего имело место их снижение, достигая к 7 сут. исходной величины. Для антивоспалительных биомаркеров ИЛ-4 и ИЛ-10 были характерны отличительная динамика и зависимость от ремоделирования миокарда. В обеих исследуемых группах содержание ИЛ после ангиопластики снижалось, достигая минимальный уровень на 3 сут. Однако, начиная с 4 сут. в группе больных с АРМ, отмечалось увеличение сывороточного содержания ИЛ-4 и ИЛ-10, прирост которых к 7 сут. составил в среднем 52-55% (p&lt;0,05). У больных с ПРМ увеличение этих ИЛ было незначительным, прирост которых находился в пределах 5,75,8%. Динамика ММП-8 также была отличительной в сравниваемых группах и коррелировала с динамикой ИЛ-4 и ИЛ-10. У больных с АРМ уровень ММП-8 снизился с 4 по 7 сут. на 46,6%, тогда как в группе с ПРМ уровень ММП в этом периоде практически не изменился, оставаясь достоверно выше контрольного в среднем на 45-53%.</p></sec><sec><title>Заключение</title><p>Заключение. В представленном исследовании сывороточное содержание основных провоспалительных биомаркеров (вчСРБ, ИЛ-1, ИЛ-6, фактор некроза опухоли альфа) в первые 7 сут. после реваскуляризации ОИМ↑STдостоверно не отличалось в группах больных с развитием АРМ и постинфарктного ПРМ. Среди антивоспалительных цитокинов динамика ИЛ-4 и ИЛ-10 зависела от ремоделирования миокарда. Их достоверное увеличение на 52-55%, начиная с 4-сут. по 7 сут. после ангиопластики наблюдалось в группе больных с АРМ, тогда как у больных с ПРМ их уровень за этот период не менялся, что позволяет предположить их прогностическую значимость. Характер изменения ММП-8 патогенетически согласуется с динамикой ИЛ-4 и ИЛ-10.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the trait of the changes of circulating level of pro- and antiinflammatory biomarkers as well as metalloproteinase 8 (MMP-8) in the first 7 days after revascularization in patients with acute myocardial infarction with ST segment elevation (STEMI) for assessment of their prognostic value regarding post-infarction remodeling pattern.</p></sec><sec><title>Material and methods</title><p>Material and methods. In 113 patients with STEMI which developed in 5 months after angioplasty adaptive myocardium remodeling (AMR) (n=56) or pathological myocardium remodeling (PMR) (n=57), determined by enzyme-linked immunosorbent assay (ELISA) method daily serum concentration of pro-inflammatory ((high sensitive C reactive protein, interleukins (IL) 1, 6, tumor necrosis factor alpha and monocyte chemoattractant protein 1)), anti-inflammatory biomarkers (IL-4, IL-10, IL-33, IL-1 receptor antagonist and heregulin-1beta) аs well as ММР-8 in the first 7 days after myocardium revascularization. According to clinic-demographic indices both groups were comparable. Obtained data have been compared with results of 20 healthy persons (control group).</p></sec><sec><title>Results</title><p>Results. The dynamics of pro-inflammatory biomarkers did not differ in patients with AMR and PMR after revascularization. It was characterized by a significant biomarker increase at 3-rd day followed by a decline toward 7-th day up to initial level. Among anti-inflammatory biomarkers IL-4 and IL-10 have manifested by a distinct dynamic in concern to myocardial remodeling pattern. In both groups these interleukins decreased after angioplasty, reaching a minimal level at 3-rd day. However, in patients with AMR since 4-th day has been established an increase of serum content of IL-4 and IL-10, their increment being at 7-th day in a range of 52-55% (p&lt;0,05). In patients with PMR the interleukins rise was negligible: 5,7-5,8%. MMP-8 dynamics also has been different in groups and was correlated with dynamics of IL-4 and IL-10. Thus, in patients with AMR its level has fallen since 4-th day up to 7-th day by 46,6%, while in group with PMR metalloproteinase level in this period practically did not change, remaining significantly higher than control by 45-53%.</p></sec><sec><title>Conclusion</title><p>Conclusion. In our study the serum content of main pro-inflammatory biomarkers (hsCRP, IL-1, IL-6, TNF-ɑ) didn’t differ in the first 7 days after revascularization in patients with adaptive and pathological postinfarction remodeling of myocardium, and thus don’t have predictive value concerning the remodeling pattern. Among anti-inflammatory cytokines dynamics of IL-4 and IL-10 differed in dependence on remodeling pattern. Their significant elevation by 52-55% from 4th up to 7th day after angioplasty was established in patients with adaptive myocardium remodeling, while in PMR their level didn’t change during this period that can emphasize their prognostic value. The character of MMP-8 change is pathogenetically correlated with dynamics of IL-4 and IL-10.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>постинфарктное ремоделирование</kwd><kwd>биомаркеры воспаления</kwd></kwd-group><kwd-group xml:lang="en"><kwd>post-infraction remodeling</kwd><kwd>inflammation biomarkers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Galli A, Lombardi F. Postinfarct left ventricular remodeling: a prevailing cause of heart failure. Cardiology Research and Practice 2016; 2016: Article ID 2579832, 12 pages, doi:10.1155/2016/2579832.</mixed-citation><mixed-citation xml:lang="en">Galli A, Lombardi F. Postinfarct left ventricular remodeling: a prevailing cause of heart failure. Cardiology Research and Practice 2016; 2016: Article ID 2579832, 12 pages, doi:10.1155/2016/2579832.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">French BA, Kramer CM. Mechanisms of post-infarct ventricular remodeling. Drug Discov today Dis Mech. 2007;4(3):185-96. doi: 10.1016/j.ddmec.2007.12.006.</mixed-citation><mixed-citation xml:lang="en">French BA, Kramer CM. Mechanisms of post-infarct ventricular remodeling. Drug Discov today Dis Mech. 2007;4(3):185-96. doi: 10.1016/j.ddmec.2007.12.006.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Borekci A, Gur M, Turkoglu C, et al. Neutrophil to lymphocyte ration predicts left ventricular remodeling in patients with ST elevation myocardial infarction aafter primary percutaneous coronary intervention. Korean Circ J. 2016;46( 1): 15-22. doi:10.4070/kcj.2016.46.1.15.</mixed-citation><mixed-citation xml:lang="en">Borekci A, Gur M, Turkoglu C, et al. Neutrophil to lymphocyte ration predicts left ventricular remodeling in patients with ST elevation myocardial infarction aafter primary percutaneous coronary intervention. Korean Circ J. 2016;46( 1): 15-22. doi:10.4070/kcj.2016.46.1.15.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pokorney SD, Rodriguez JF, Ortiz JT, et al. Infarct healing is a dynamic process following acute myocardial infarction. J of Cardiovasc Magnetic Resonance. 2012;14:62-72. doi:10.1186/1532-429X-14-62.</mixed-citation><mixed-citation xml:lang="en">Pokorney SD, Rodriguez JF, Ortiz JT, et al. Infarct healing is a dynamic process following acute myocardial infarction. J of Cardiovasc Magnetic Resonance. 2012;14:62-72. doi:10.1186/1532-429X-14-62.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. JACC. 2016;67(17):2050-60.</mixed-citation><mixed-citation xml:lang="en">Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. JACC. 2016;67(17):2050-60.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Seropian IM, Toldo S, Van Tassell BW, et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. JACC. 2014;63(16):1593-603. doi:10.1016/j.jacc.2014.01.014.</mixed-citation><mixed-citation xml:lang="en">Seropian IM, Toldo S, Van Tassell BW, et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. JACC. 2014;63(16):1593-603. doi:10.1016/j.jacc.2014.01.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909, doi:10.1136/bmj.j190IL-10 cytokine family. Mediators of Inflammation. 2015; http://dx.org/10.1155/2015/764641.</mixed-citation><mixed-citation xml:lang="en">Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909, doi:10.1136/bmj.j190IL-10 cytokine family. Mediators of Inflammation. 2015; http://dx.org/10.1155/2015/764641.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mulvagh S, Quinones M, Kleiman NS, et al. Estimation of Left Ventricular End-Diastolic Pressure From Doppler Transmitral Flow Velocity in Cardiac Patients Independent of Systolic Performance. JAAC. 1992;20(1):112-9.</mixed-citation><mixed-citation xml:lang="en">Mulvagh S, Quinones M, Kleiman NS, et al. Estimation of Left Ventricular End-Diastolic Pressure From Doppler Transmitral Flow Velocity in Cardiac Patients Independent of Systolic Performance. JAAC. 1992;20(1):112-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodeling. Nat Rev Cardiol. 2014;11:255-65. doi:101038/nrcardio.2014.28.</mixed-citation><mixed-citation xml:lang="en">Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodeling. Nat Rev Cardiol. 2014;11:255-65. doi:101038/nrcardio.2014.28.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ong SB, Hernandez-Resendiz S, Crespo-Alvilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles and novel therapeutic opportunities. Pharamacol Therapeut. 2018;186:73-87. doi: 10.1016/j.pharmthera.2018.01.001.</mixed-citation><mixed-citation xml:lang="en">Ong SB, Hernandez-Resendiz S, Crespo-Alvilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles and novel therapeutic opportunities. Pharamacol Therapeut. 2018;186:73-87. doi: 10.1016/j.pharmthera.2018.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Anzai T. Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J. 2013;77:580-7. doi:10.1253/circj.CJ-13-0013.</mixed-citation><mixed-citation xml:lang="en">Anzai T. Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J. 2013;77:580-7. doi:10.1253/circj.CJ-13-0013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96(5):2304-10. doi:10.1172/JCI118286.</mixed-citation><mixed-citation xml:lang="en">Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96(5):2304-10. doi:10.1172/JCI118286.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Thuren T, Zalewski A, Libbi P. Interleukin-13 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605. doi:10.1016/j.ahj.2011.06.012.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Thuren T, Zalewski A, Libbi P. Interleukin-13 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605. doi:10.1016/j.ahj.2011.06.012.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
